ACROBIOSYSTEMS CO.,LTD. — Investor Relations & Filings
ACROBIOSYSTEMS CO.,LTD. is a global biotechnology company specializing in the development and manufacturing of high-quality recombinant proteins and critical reagents for the life sciences industry. The company provides a comprehensive portfolio of products designed to accelerate the development of target therapeutics, including antibodies, cell and gene therapies, and vaccines. Key offerings include a wide range of biotinylated proteins, enzymes, and assay kits characterized by high bioactivity and batch-to-batch consistency. ACROBIOSYSTEMS supports drug discovery and clinical development through specialized platforms for protein engineering and characterization. Its products serve a diverse client base of pharmaceutical companies, biotechnology firms, and academic research institutions worldwide, focusing on therapeutic areas such as oncology, immunology, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于调整2022年限制性股票激励计划首次及预留授予价格的公告 | 2023-05-08 | Chinese | |
| 监事会关于公司2022年限制性股票激励计划预留授予部分激励对象名单（预留授予日）的核查意见 | 2023-05-08 | Chinese | |
| 关于股东减持计划期限届满暨后续减持计划的预披露公告 | 2023-05-05 | Chinese | |
| 关于2023年第一季度报告披露的提示性公告 | 2023-04-25 | Chinese | |
| 董事会决议公告 | 2023-04-25 | Chinese | |
| 招商证券股份有限公司关于北京百普赛斯生物科技股份有限公司2022年度内部控制自我评价报告的核查意见 | 2023-04-25 | Chinese |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2023
15 filings
| |||||
| 44576051 | 关于调整2022年限制性股票激励计划首次及预留授予价格的公告 | 2023-05-08 | Chinese | ||
| 44576044 | 监事会关于公司2022年限制性股票激励计划预留授予部分激励对象名单（预留授予日）的核查意见 | 2023-05-08 | Chinese | ||
| 44576034 | 关于股东减持计划期限届满暨后续减持计划的预披露公告 | 2023-05-05 | Chinese | ||
| 44576021 | 关于2023年第一季度报告披露的提示性公告 | 2023-04-25 | Chinese | ||
| 44576006 | 董事会决议公告 | 2023-04-25 | Chinese | ||
| 44575994 | 招商证券股份有限公司关于北京百普赛斯生物科技股份有限公司2022年度内部控制自我评价报告的核查意见 | 2023-04-25 | Chinese | ||
| 44575986 | 2022年度内部控制自我评价报告 | 2023-04-25 | Chinese | ||
| 44575966 | 公司章程修正案 | 2023-04-25 | Chinese | ||
| 44575952 | 关于公司董事、监事、高级管理人员薪酬方案的公告 | 2023-04-25 | Chinese | ||
| 44575944 | 2022年度监事会工作报告 | 2023-04-25 | Chinese | ||
| 44575935 | 2022年度独立董事述职报告（张勇） | 2023-04-25 | Chinese | ||
| 44575931 | 2022年度独立董事述职报告（许娟红） | 2023-04-25 | Chinese | ||
| 44575921 | 非经营性资金占用及其他关联资金往来情况专项说明 | 2023-04-25 | Chinese | ||
| 44575868 | 2022年度独立董事述职报告（刘峰） | 2023-04-25 | Chinese | ||
| 44575856 | 独立董事关于第一届董事会第二十二次会议相关事项的独立意见 | 2023-04-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ACROBIOSYSTEMS CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56034/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56034 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56034 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56034 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56034}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ACROBIOSYSTEMS CO.,LTD. (id: 56034)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.